RIP Raptiva?
Laura
L
DeFrancesco
D000911:Antibodies, Monoclonal / Q000009:adverse effects* / Q000627:therapeutic use; D061067:Antibodies, Monoclonal, Humanized; D006801:Humans; D007968:Leukoencephalopathy, Progressive Multifocal / Q000139:chemically induced* / Q000401:mortality*; D011358:Product Surveillance, Postmarketing; D011565:Psoriasis / Q000188:drug therapy; D018570:Risk Assessment; D014481:United States
D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; C472181:efalizumab